Precision BioSciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTIL research report →
About the company
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
- CEO
- Juli Blanche
- IPO
- 2019
- Employees
- 108
- HQ
- Durham, NC, US
Price Chart
- Market Cap
- $78.25M
- P/E
- -1.76
- P/S
- 1.74
- P/B
- 1.03
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
- Gross Margin
- 96.95%
- Op Margin
- -86.77%
- Net Margin
- -98.70%
- ROE
- -81.24%
- ROIC
- -28.40%
- Revenue
- $34.26M · -50.12%
- Net Income
- $-46,609,000 · -750.33%
- EPS
- $-3.63 · -445.71%
- Op Income
- $-52,148,000
- FCF YoY
- -12.32%
- 52W High
- $8.82
- 52W Low
- $3.53
- 50D MA
- $7.08
- 200D MA
- $5.62
- Beta
- 1.28
- Avg Volume
- 315.43K
Get TickerSpark's AI analysis on DTIL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 3, 26 | Brown Melinda | other | 20,979 |
| Jun 3, 26 | Frankel Stanley | other | 20,979 |
| Jun 3, 26 | Germano Geno J | other | 20,979 |
| Jun 3, 26 | Pire Shari Lisa | other | 20,979 |
| Jun 3, 26 | Buehler Kevin | other | 20,979 |
| May 20, 26 | Buehler Kevin | other | 21,000 |
| May 20, 26 | Buehler Kevin | other | 21,000 |
| May 20, 26 | Frankel Stanley | other | 21,000 |
| May 20, 26 | Frankel Stanley | other | 21,000 |
| May 20, 26 | Brown Melinda | other | 21,000 |
Our DTIL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on DTIL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.